Business & Economy · 6 views
Vertex’s executive chairman: Here’s how we got our drug-trial success rate over 70% when the industry’s is 10% to 20%
More bets don’t necessarily produce more successes
AI Summary
Vertex’s executive chairman explained that the company’s drug‑trial success rate has risen above 70%, far higher than the industry average of 10% to 20%. He attributed this to a strategy of making fewer, smarter bets rather than many broad R&D investments. The approach focuses on targeted, high‑confidence projects, reducing the typical 10‑15‑year development cycle and the 90% failure rate that plagues the sector. This shift aims to improve efficiency and outcomes in a field where even large firms can experience multiple trial failures in a single week.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Business & Economy
Continue reading recent Business & Economy coverage
- Mark Cuban went 7 years without a vacation and Jeff Bezos worked 12-hour days. That kind of obsession is the secret to success, business coach saysContinue reading
- I moved from the US to the South of France at 56. I'm so relaxed here, my resting heart rate dropped almost overnight.Continue reading
- Stocks are in a correction heading into the Thanksgiving holiday. What to brace for next.Continue reading
- A US Army officer went inside Ukraine’s ‘Killhouse.’ Here’s what he brought home to his drone course.Continue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow